Drug makers’ sales forces have continued to shrink over the last few years. As the shift from primary fields to specialty arenas and the loss of patent protection for major products have transformed drug makers’ product mix, fewer sales reps…
COMMENTARY
Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews
The tactic selected by the Japan Generic Medicines Association (JGA) to prevent the government from introducing a 50% pricing rule for first generics has received mixed reactions from health ministry bureaucrats and industry insiders. Some at the Ministry of Health,…
To read the full story
Related Article
COMMENTARY
- Drug Makers Downsizing Sales Forces to Increase Efficiency; Launch of Redundancy Programs to Be Continued
October 15, 2021
- Pharma on Alert for Possible Repeat of Minister Deal on Drug Pricing Reform
October 13, 2021
- 5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
September 29, 2021
- CEA Reform Debate Going into Full Throttle, Chuikyo Consensus to Be Drawn as Early as October
August 3, 2021
- Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
If you were able to make more money at a company you found less desirable than your current one, would it be worth it? Conversely, would you move to a better company and a better role and accept less pay?…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…